Regeneus Focused on Developing Adipose - Derived Allogeneic MSC Product W/ Added Secretions

Thursday, 10 August 2017

Regeneus is a firm that conducts research and development in adipose-derived cellular therapies for both human and veterinary use. In December 2016 the firm out-licensed the exclusive Japanese manufacturing rights for their adipose-derived allogeneic mesenchymal stem cell (MSC) product, Progenza, to AGC Asahi Glass. In line with this development, the two firms established a joint-venture, Regeneus Japan, in Shibuya, to assist in their search for a commercialisation partner for Progenza in Japan. On June 9, 2017 Regeneus’ CEO, Mr. John Martin, and the firm’s Head of Licensing and Alliances, Dr. Duncan Thomson, answered some of this newspaper’s questions on their plans for Japan.

Read here the full interview in pdf